Table of Contents
ISRN Pharmacology
Volume 2014 (2014), Article ID 601653, 12 pages
http://dx.doi.org/10.1155/2014/601653
Review Article

Intravesical Liposome and Antisense Treatment for Detrusor Overactivity and Interstitial Cystitis/Painful Bladder Syndrome

1Department of Urology, University of Pittsburgh, PA 15213, USA
2Department of Urology, William Beaumont School of Medicine, Royal oak, MI 48073, USA

Received 18 July 2013; Accepted 24 October 2013; Published 16 January 2014

Academic Editors: S. Mingmalairak, T. W. Stone, and S.-N. Wu

Copyright © 2014 Pradeep Tyagi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Parkin, C. Shea, and G. R. Sant, “Intravesical dimethyl sulfoxide (DMSO) for interstitial cystitis—a practical approach,” Urology, vol. 49, no. 5, pp. 105–107, 1997. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Dowson, J. Watkins, M. S. Khan, P. Dasgupta, and A. Sahai, “Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates,” European Urology, vol. 61, no. 4, pp. 834–839, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Kaufman, V. Tyagi, M. Anthony, M. B. Chancellor, and P. Tyagi, “State of the art in intravesical therapy for lower urinary tract symptoms,” Reviews in Urology, vol. 12, pp. e181–e189, 2010. View at Google Scholar
  4. N. Yoshimura and M. B. Chancellor, “Current and future pharmacological treatment for overactive bladder,” Journal of Urology, vol. 168, no. 5, pp. 1897–1913, 2002. View at Google Scholar · View at Scopus
  5. K. A. Killinger, J. A. Boura, and K. M. Peters, “Pain in interstitial cystitis/bladder pain syndrome: do characteristics differ in ulcerative and non-ulcerative subtypes?” International Urogynecology Journal, vol. 24, no. 8, pp. 1295–1301, 2013. View at Publisher · View at Google Scholar
  6. J. C. Nickel, P. Hanno, K. Kumar, and H. Thomas, “Second multicenter, randomized, double-blind, parallel-group evaluation of effectiveness and safety of intravesical sodium chondroitin sulfate compared with inactive vehicle control in subjects with interstitial cystitis/bladder pain syndrome,” Urology, vol. 79, no. 6, pp. 1220–1225, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. P. M. Hanno, “Analysis of long-term elmiron therapy for interstitial cystitis,” Urology, vol. 49, no. 5, pp. 93–99, 1997. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Giannantoni, V. Bini, R. Dmochowski et al., “Reply to Claus Riedl's letter to the editor re: antonella Giannantoni, Vittorio Bini, Roger Dmochowski et al. Contemporary management of the painful bladder: a systematic review,” European Urology, vol. 61, no. 5, pp. 29–53, 2012. View at Google Scholar · View at Scopus
  9. M. C. Lai, Y. C. Kuo, and H. C. Kuo, “Intravesical hyaluronic acid for interstitial cystitis/painful bladder syndrome: a comparative randomized assessment of different regimens,” International Journal of Urology, vol. 20, pp. 203–207, 2013. View at Google Scholar
  10. J. Eldrup, J. Thorup, and S. L. Nielsen, “Permeability and ultrastructure of human bladder epithelium,” British Journal of Urology, vol. 55, no. 5, pp. 488–492, 1983. View at Google Scholar · View at Scopus
  11. C. L. Parsons, D. Boychuk, S. Jones, R. Hurst, and H. Callahan, “Bladder surface glycosaminoglycans: an epithelial permeability barrier,” Journal of Urology, vol. 143, no. 1, pp. 139–142, 1990. View at Google Scholar · View at Scopus
  12. Y. Kim, N. Yoshimura, H. Masuda, F. De Miguel, and M. B. Chancellor, “Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways,” Urology, vol. 65, no. 2, pp. 238–242, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. V. Tyagi, B. J. Philips, R. Su et al., “Differential expression of functional cannabinoid receptors in human bladder detrusor and urothelium,” Journal of Urology, vol. 181, no. 4, pp. 1932–1938, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. B. J. Philips, M. C. Smaldone, V. L. Erickson, N. Yoshimura, M. B. Chancellor, and P. Tyagi, “Differential expression of neurokinin receptor subtypes in urothelium and detrusor of human bladder,” Journal of Urology, vol. 179, article 354, 2008. View at Google Scholar
  15. S. A. Baker, G. W. Hennig, J. Han, F. C. Britton, T. K. Smith, and S. D. Koh, “Methionine and its derivatives increase bladder excitability by inhibiting stretch-dependent K+ channels,” British Journal of Pharmacology, vol. 153, no. 6, pp. 1259–1271, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. J. M. Beckel, A. Kanai, S.-J. Lee, W. C. De Groat, and L. A. Birder, “Expression of functional nicotinic acetylcholine receptors in rat urinary bladder epithelial cells,” American Journal of Physiology—Renal Physiology, vol. 290, no. 1, pp. F103–F110, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. L. A. Birder, A. J. Kanai, W. C. De Groat et al., “Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 23, pp. 13396–13401, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Tyagi, C. A. Thomas, N. Yoshimura, and M. B. Chancellor, “Investigations into the presence of functional ß1, ß2 and ß3-adrenoceptors in urothelium and detrusor of human bladder,” International Brazilian Journal of Urology, vol. 35, no. 1, pp. 76–83, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. A. T. Hanna-Mitchell, J. M. Beckel, S. Barbadora, A. J. Kanai, W. C. de Groat, and L. A. Birder, “Non-neuronal acetylcholine and urinary bladder urothelium,” Life Sciences, vol. 80, no. 24-25, pp. 2298–2302, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. C. P. Smith, D. A. Gangitano, A. Munoz et al., “Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury,” Neurochemistry International, vol. 52, no. 6, pp. 1068–1075, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. Y.-C. Chuang, C. A. Thomas, S. Tyagi, N. Yoshimura, P. Tyagi, and M. B. Chancellor, “Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity,” International Urogynecology Journal and Pelvic Floor Dysfunction, vol. 19, no. 10, pp. 1353–1357, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Kim, N. Yoshimura, H. Masuda, F. D. Miguel, and M. B. Chancellor, “Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity,” BJU International, vol. 97, no. 2, pp. 400–403, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Tyagi, P. Tyagi, S. Van-le, N. Yoshimura, M. B. Chancellor, and F. de Miguel, “Qualitative and quantitative expression profile of muscarinic receptors in human urothelium and detrusor,” Journal of Urology, vol. 176, no. 4, pp. 1673–1678, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Gregoriadis and B. E. Ryman, “Liposomes as carriers of enzymes or drugs: a new approach to the treatment of storage diseases,” Biochemical Journal, vol. 124, no. 5, p. 58, 1971. View at Google Scholar · View at Scopus
  25. G. Gregoriadis, S. Jain, I. Papaioannou, and P. Laing, “Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids,” International Journal of Pharmaceutics, vol. 300, no. 1-2, pp. 125–130, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Sapra, P. Tyagi, and T. M. Allen, “Ligand-targeted liposomes for cancer treatment,” Current Drug Delivery, vol. 2, no. 4, pp. 369–381, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Gregoriadis, G. Dapergolas, and E. D. Neerunjun, “Penetration of target areas in the rat by liposome associated agents administered parenterally and intragastrically,” Biochemical Society Transactions, vol. 4, no. 2, pp. 256–259, 1976. View at Google Scholar · View at Scopus
  28. G. Gregoriadis, “Engineering liposomes for drug delivery: progress and problems,” Trends in Biotechnology, vol. 13, no. 12, pp. 527–537, 1995. View at Publisher · View at Google Scholar · View at Scopus
  29. G. Gregoriadis and A. C. Allison, “Entrapment of proteins in liposomes prevents allergic reactions in pre immunised mice,” FEBS Letters, vol. 45, no. 1, pp. 71–74, 1974. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Lee, S. Dausch, C. Maierhofer, and D. Dausch, “A new therapy concept with a liposome eye spray for the treatment of the ‘dry eye’,” Klinische Monatsblatter fur Augenheilkunde, vol. 221, no. 10, pp. 825–836, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. D. Dausch, S. Lee, S. Dausch, J. C. Kim, G. Schwert, and W. Michelson, “Comparative study of treatment of the dry eye syndrome due to disturbances of the tear film lipid layer with lipid-containing tear substitutes: efficacy of lipid-containing tear substitutes,” Klinische Monatsblatter fur Augenheilkunde, vol. 223, no. 12, pp. 974–983, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Ebrahim, G. A. Peyman, and P. J. Lee, “Applications of liposomes in ophthalmology,” Survey of Ophthalmology, vol. 50, no. 2, pp. 167–182, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Nirmal, P. Tyagi, L. Dang et al., “Endocytosis uptake of liposomes in urothelium cells detected by transmission electron microscopy,” The Journal of Urology, vol. 187, article e15, 2012. View at Google Scholar
  34. D. N. Frangos, J. J. Killion, D. Fan, R. Fishbeck, A. C. Von Eschenbach, and I. J. Fidler, “The development of liposomes containing interferon alpha for the intravesical therapy of human superficial bladder cancer,” Journal of Urology, vol. 143, no. 6, pp. 1252–1266, 1990. View at Google Scholar · View at Scopus
  35. J. W. Johnson, R. Nayar, J. J. Killion, A. C. Von Eschenbach, and I. J. Fidler, “Binding of liposomes to human bladder tumor epithelial cell lines: implications for an intravesical drug delivery system for the treatment of bladder cancer,” Selective Cancer Therapeutics, vol. 5, no. 4, pp. 147–155, 1989. View at Google Scholar · View at Scopus
  36. Y.-C. Chuang, M. B. Chancellor, S. Seki et al., “Intravesical protamine sulfate and potassium chloride as a model for bladder hyperactivity,” Urology, vol. 61, no. 3, pp. 664–670, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Kaufman, P. Tyagi, and M. B. Chancellor, “Intravesical liposomal (Lp08) instillation protects bladder urothelium from chemical irritation,” The Journal of Urology, vol. 181, article 539, 2009. View at Google Scholar
  38. P. Tyagi, M. B. Chancellor, Z. Li et al., “Urodynamic and immunohistochemical evaluation of intravesical capsaicin delivery using thermosensitive hydrogel and liposomes,” Journal of Urology, vol. 171, no. 1, pp. 483–489, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. M. O. Fraser, Y.-C. Chuang, P. Tyagi et al., “Intravesical liposome administration—a novel treatment for hyperactive bladder in the rat,” Urology, vol. 61, no. 3, pp. 656–663, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Tyagi, M. Chancellor, N. Yoshimura, and L. Huang, “Activity of different phospholipids in attenuating hyperactivity in bladder irritation,” BJU International, vol. 101, no. 5, pp. 627–632, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. Y. Sun and T. C. Chai, “Effects of dimethyl sulphoxide and heparin on stretch-activated ATP release by bladder urothelial cells from patients with interstitial cystitis,” BJU International, vol. 90, no. 4, pp. 381–385, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. J. J. Bade, “A placebo-controlled study of intravesical pentosanpolysulphate for the treatment of interstitial cystitis,” British Journal of Urology, vol. 79, no. 2, pp. 168–171, 1997. View at Google Scholar · View at Scopus
  43. P. Tyagi, V. C. Hsieh, N. Yoshimura, J. Kaufman, and M. B. Chancellor, “Instillation of liposomes vs dimethyl sulphoxide or pentosan polysulphate for reducing bladder hyperactivity,” BJU International, vol. 104, no. 11, pp. 1689–1692, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. W.-C. Lee, C.-T. Chien, H.-J. Yu, and S.-W. Lee, “Bladder dysfunction in rats with metabolic syndrome induced by long-term fructose feeding,” Journal of Urology, vol. 179, no. 6, pp. 2470–2476, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. J. I. Gillespie, G. A. Van Koeveringe, S. G. De Wachter, and J. De Vente, “On the origins of the sensory output from the bladder: the concept of afferent noise,” BJU International, vol. 103, no. 10, pp. 1324–1333, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. W. C. Lee, P. H. Chiang, Y. L. Tain, C. C. Wu, and Y. C. Chuang, “Sensory dysfunction of bladder mucosa and bladder oversensitivity in a rat model of metabolic syndrome,” PloS ONE, vol. 7, Article ID e45578, 2012. View at Google Scholar
  47. Y.-C. Chuang, W.-C. Lee, W.-C. Lee, and P.-H. Chiang, “Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome,” Journal of Urology, vol. 182, no. 4, pp. 1393–1400, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. W.-C. Lee, Y.-C. Chuang, W.-C. Lee, and P.-H. Chiang, “Safety and dose flexibility clinical evaluation of intravesical liposome in patients with interstitial cystitis or painful bladder syndrome,” Kaohsiung Journal of Medical Sciences, vol. 27, no. 10, pp. 437–440, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. S. T. Truschel, E. Wang, W. G. Ruiz et al., “Stretch-regulated exocytosis/endocytosis in bladder umbrella cells,” Molecular Biology of the Cell, vol. 13, no. 3, pp. 830–846, 2002. View at Publisher · View at Google Scholar · View at Scopus
  50. M. B. Chancellor and W. C. De Groat, “Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder,” Journal of Urology, vol. 162, no. 1, pp. 3–11, 1999. View at Publisher · View at Google Scholar · View at Scopus
  51. D. S. Byrne, A. Das, J. Sedor et al., “Effect of intravesical capsaicin and vehicle on bladder integrity in control and spinal cord injured rats,” Journal of Urology, vol. 159, no. 3, pp. 1074–1078, 1998. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Mandal and K.-D. Lee, “Listeriolysin O-liposome-mediated cytosolic delivery of macromolecule antigen in vivo: enhancement of antigen-specific cytotoxic T lymphocyte frequency, activity, and tumor protection,” Biochimica et Biophysica Acta, vol. 1563, no. 1-2, pp. 7–17, 2002. View at Publisher · View at Google Scholar · View at Scopus
  53. Y.-C. Chuang, P. Tyagi, C.-C. Huang et al., “Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin a delivery using liposomes,” Journal of Urology, vol. 182, no. 2, pp. 786–792, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. Y.-C. Chuang, N. Yoshimura, C.-C. Huang, P.-H. Chiang, and M. B. Chancellor, “Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats,” Journal of Urology, vol. 172, no. 4, pp. 1529–1532, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. S. P. Petrou, A. S. Parker, J. E. Crook, A. Rogers, D. Metz-Kudashick, and D. D. Thiel, “Botulinum A toxin/dimethyl sulfoxide bladder instillations for women with refractory idiopathic detrusor overactivity: a phase 1/2 study,” Mayo Clinic Proceedings, vol. 84, no. 8, pp. 702–706, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. P. Caccin, O. Rossetto, M. Rigoni, E. Johnson, G. Schiavo, and C. Montecucco, “VAMP/synaptobrevin cleavage by tetanus and botulinum neurotoxins is strongly enhanced by acidic liposomes,” FEBS Letters, vol. 542, no. 1–3, pp. 132–136, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. M. L. Stephenson and P. C. Zamecnik, “Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide,” Proceedings of the National Academy of Sciences of the United States of America, vol. 75, no. 1, pp. 285–288, 1978. View at Google Scholar · View at Scopus
  58. H. Dadgostar and N. Waheed, “The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration,” Eye, vol. 22, no. 6, pp. 761–767, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. C. Gebhard, G. Huard, E. A. Kritikou, and J. C. Tardif, “Apolipoprotein B antisense inhibition—update on mipomersen,” Current Pharmaceutical Design, vol. 919, no. 17, pp. 3132–3142, 2013. View at Google Scholar
  60. T. Yokota, E. Hoffman, and S. Takeda, “Antisense oligo-mediated multiple exon skipping in a dog model of duchenne muscular dystrophy,” Methods in Molecular Biology, vol. 709, pp. 299–312, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. B. L. Jacobs, M. C. Smaldone, V. Tyagi et al., “Increased nerve growth factor in neurogenic overactive bladder and interstitial cystitis patients,” The Canadian Journal of Urology, vol. 17, no. 1, pp. 4989–4994, 2010. View at Google Scholar · View at Scopus
  62. H.-T. Liu and H.-C. Kuo, “Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis,” Urology, vol. 70, no. 3, pp. 463–468, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. H. T. Liu and H. C. Kuo, “Increased urine and serum nerve growth factor levels in interstitial cystitis suggest chronic inflammation is involved in the pathogenesis of disease,” PloS ONE, vol. 7, Article ID e44687, 2012. View at Google Scholar
  64. N. Yoshimura, N. E. Bennett, Y. Hayashi et al., “Bladder overactivity and hyperexcitability of bladder afferent neurons after intrathecal delivery of nerve growth factor in rats,” Journal of Neuroscience, vol. 26, no. 42, pp. 10847–10855, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. S. Seki, K. Sasaki, Y. Igawa et al., “Suppression of detrusor-sphincter dyssynergia by immunoneutralization of nerve growth factor in lumbosacral spinal cord in spinal cord injured rats,” Journal of Urology, vol. 171, no. 1, pp. 478–482, 2004. View at Publisher · View at Google Scholar · View at Scopus
  66. R. J. Evans, R. M. Moldwin, N. Cossons, A. Darekar, I. W. Mills, and D. Scholfield, “Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis,” Journal of Urology, vol. 185, no. 5, pp. 1716–1721, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. P. Tyagi, R. Banerjee, S. Basu, N. Yoshimura, M. Chancellor, and L. Huang, “Intravesical antisense therapy for cystitis using TAT-peptide nucleic acid conjugates,” Molecular Pharmaceutics, vol. 3, no. 4, pp. 398–406, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. D. C. Molliver, D. E. Wright, M. L. Leitner et al., “IB4-binding DRG neurons switch from NGF to GDNF dependence in early postnatal life,” Neuron, vol. 19, no. 4, pp. 849–861, 1997. View at Publisher · View at Google Scholar · View at Scopus
  69. M. Tyagi, M. Rusnati, M. Presta, and M. Giacca, “Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans,” Journal of Biological Chemistry, vol. 276, no. 5, pp. 3254–3261, 2001. View at Publisher · View at Google Scholar · View at Scopus
  70. E. Uhlmann, A. Ryte, and A. Peyman, “Studies on the mechanism of stabilization of partially phosphorothioated oligonucleotides against nucleolytic degradation,” Antisense and Nucleic Acid Drug Development, vol. 7, no. 4, pp. 345–350, 1997. View at Google Scholar · View at Scopus
  71. M. Nogawa, T. Yuasa, S. Kimura et al., “Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer,” Journal of Clinical Investigation, vol. 115, no. 4, pp. 978–985, 2005. View at Publisher · View at Google Scholar · View at Scopus
  72. M. Kashyap, N. Kawamorita, V. Tyagi et al., “Downregulation of NGF expression in the bladder by antisense oligoucleotides as new treatment for overactive bladder,” Journal of Urology, vol. 27190, no. 2, pp. 757–764, 2013. View at Publisher · View at Google Scholar
  73. C.-J. Arum, Y. Kodama, N. Rolim et al., “A rat model of intravesical delivery of small interfering RNA for studying urinary carcinoma,” World Journal of Urology, vol. 28, no. 4, pp. 479–485, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. C. E. Blietz, B. Thode, M. Hauses et al., “In vivo studies on the availability and toxicity of antisense oligonucleotides in bladder cancer,” In Vivo, vol. 23, no. 1, pp. 13–19, 2009. View at Google Scholar · View at Scopus
  75. D. Oddiah, P. Anand, S. B. McMahon, and M. Rattray, “Rapid increase of NGF, BDNF and NT-3 mRNAs in inflamed bladder,” NeuroReport, vol. 9, no. 7, pp. 1455–1458, 1998. View at Google Scholar · View at Scopus
  76. M. R. Saban, H. Hellmich, N. B. Nguyen, J. Winston, T. G. Hammond, and R. Saban, “Time course of LPS-induced gene expression in a mouse model of genitourinary inflammation,” Physiol Genomics, vol. 5, no. 3, pp. 147–160, 2001. View at Google Scholar · View at Scopus
  77. B. Schnegelsberg, T. T. Sun, G. Cain et al., “Overexpression of NGF in mouse urothelium leads to neuronal hyperinnervation, pelvic sensitivity, and changes in urinary bladder function,” The American Journal of Physiology—Regulatory, Integrative and Comparative Physiology, vol. 298, no. 5, pp. R534–R547, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. S. Cardenas, M. Scuri, L. Samsell et al., “Neurotrophic and neuroimmune responses to early-life Pseudomonas aeruginosa infection in rat lungs,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 299, no. 3, pp. L334–L344, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. K. Nakamura, F. Tan, Z. Li, and C. J. Thiele, “NGF activation of TrkA induces vascular endothelial growth factor expression via induction of hypoxia-inducible factor-1α,” Molecular and Cellular Neuroscience, vol. 46, no. 2, pp. 498–506, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. S. Othumpangat, M. Regier, and G. Piedimonte, “Nerve growth factor modulates human rhinovirus infection in airway epithelial cells by controlling ICAM-1 expression,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 15302, pp. L1057–L1066, 2012. View at Google Scholar
  81. H. Jung, P. T. Toth, F. A. White, and R. J. Miller, “Monocyte chemoattractant protein-1 functions as a neuromodulator in dorsal root ganglia neurons,” Journal of Neurochemistry, vol. 104, no. 1, pp. 254–263, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. F. A. White, H. Jung, and R. J. Miller, “Chemokines and the pathophysiology of neuropathic pain,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 51, pp. 20151–20158, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. G. Banisadr, R.-D. Gosselin, P. Mechighel, W. Rostène, P. Kitabgi, and S. M. Parsadaniantz, “Constitutive neuronal expression of CCR2 chemokine receptor and its colocalization with neurotransmitters in normal rat brain: functional effect of MCP-1/CCL2 on calcium mobilization in primary cultured neurons,” Journal of Comparative Neurology, vol. 492, no. 2, pp. 178–192, 2005. View at Publisher · View at Google Scholar · View at Scopus
  84. S. Bhangoo, D. Ren, R. J. Miller et al., “Delayed functional expression of neuronal chemokine receptors following focal nerve demyelination in the rat: a mechanism for the development of chronic sensitization of peripheral nociceptors,” Molecular Pain, vol. 3, article 38, 2007. View at Publisher · View at Google Scholar · View at Scopus
  85. T. Maeda, N. Kiguchi, Y. Kobayashi, T. Ikuta, M. Ozaki, and S. Kishioka, “Leptin derived from adipocytes in injured peripheral nerves facilitates development of neuropathic pain via macrophage stimulation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 31, pp. 13076–13081, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. H. Kajiwara, M. Yasuda, N. Kumaki, T. Shibayama, and Y. Osamura, “Expression of carbohydrate antigens (SSEA-1, Sialyl-Lewis X, DU-PAN-2 and CA19-9) and E-selectin in urothelial carcinoma of the renal pelvis, ureter, and urinary bladder,” Tokai Journal of Experimental and Clinical Medicine, vol. 30, no. 3, pp. 177–182, 2005. View at Google Scholar · View at Scopus
  87. A. M. S. Assreuy, G. J. Martins, M. E. F. Moreira et al., “Prevention of cyclophosphamide-induced hemorrhagic cystitis by glucose- mannose binding plant lectins,” Journal of Urology, vol. 161, no. 6, pp. 1988–1993, 1999. View at Publisher · View at Google Scholar · View at Scopus
  88. S. M. Vinson, A. Rickard, J. S. Ryerse, and J. McHowat, “Neutrophil adherence to bladder microvascular endothelial cells following platelet-activating factor acetylhydrolase inhibition,” Journal of Pharmacology and Experimental Therapeutics, vol. 314, no. 3, pp. 1241–1247, 2005. View at Publisher · View at Google Scholar · View at Scopus
  89. M. Green, A. Filippou, G. Sant, and T. C. Theoharides, “Expression of intercellular adhesion molecules in the bladder of patients with interstitial cystitis,” Urology, vol. 63, no. 4, pp. 688–693, 2004. View at Publisher · View at Google Scholar · View at Scopus
  90. M. Leppilahti, P. Hellström, and T. L. J. Tammela, “Effect of diagnostic hydrodistension and four intravesical hyaluronic acid instillations on bladder ICAM-1 intensity and association of ICAM-1 intensity with clinical response in patients with interstitial cystitis,” Urology, vol. 60, no. 1, pp. 46–51, 2002. View at Publisher · View at Google Scholar · View at Scopus
  91. A. T. Corcoran, N. Yoshimura, V. Tyagi, B. Jacobs, W. Leng, and P. Tyagi, “Mapping the cytokine profile of painful bladder syndrome/interstitial cystitis in human bladder and urine specimens,” World Journal of Urology, vol. 31, no. 1, pp. 241–246, 2013. View at Publisher · View at Google Scholar · View at Scopus
  92. S. Garrean, X.-P. Gao, V. Brovkovych et al., “Caveolin-1 regulates NF-κB activation and lung inflammatory response to sepsis induced by lipopolysaccharide,” Journal of Immunology, vol. 177, no. 7, pp. 4853–4860, 2006. View at Google Scholar · View at Scopus
  93. M. R. Kang, G. Yang, R. F. Place et al., “Intravesical delivery of small activating RNA formulated into lipid nanoparticles inhibits orthotopic bladder tumor growth,” Cancer Research, vol. 172, pp. 5069–5079, 2012. View at Google Scholar
  94. P. Tyagi, D. Barclay, R. Zamora et al., “Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study,” International Urology and Nephrology, vol. 42, no. 3, pp. 629–635, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. P. Tyagi, B. L. Jacobs, D. Barcaly et al., “Urine levels of inflammatory chemokines can be novel biomarkers for the overactive bladder,” The Journal of Urology, vol. 181, article 588, 2009. View at Google Scholar
  96. P. Tyagi, V. Tyagi, D. Bui et al., “Discrimination Of OAB from IC/PBS by multivariate data modeling of urinary proteins,” The Journal of Urology, vol. 183, pp. e614–e6e5, 2010. View at Google Scholar
  97. P. Tyagi, D. Nikolavsky, Y. Vodovotz et al., “Urine levels of selected chemokines positively correlate with lower bladder capacity and psychometric scores in Ic/Pbs patients,” The Journal of Urology, vol. 181, article 21, 2009. View at Google Scholar
  98. R. Weissleder and V. Ntziachristos, “Shedding light onto live molecular targets,” Nature Medicine, vol. 9, no. 1, pp. 123–128, 2003. View at Publisher · View at Google Scholar · View at Scopus
  99. C. Bremer, V. Ntziachristos, and R. Weissleder, “Optical-based molecular imaging: contrast agents and potential medical applications,” European Radiology, vol. 13, no. 2, pp. 231–243, 2003. View at Google Scholar · View at Scopus
  100. U. Mahmood and R. Weissleder, “Near-infrared optical imaging of proteases in cancer,” Molecular Cancer Therapeutics, vol. 2, pp. 489–496, 2003. View at Google Scholar
  101. J. Kaufman, H. Hensley, J. Jacobs et al., “Non-invasive imaging of near infrafred dye labeled liposomes facilitates evaluation of bioresidence time,” The Journal of Urology, vol. 183, article e628, 2010. View at Google Scholar
  102. Y.-X. J. Wang, “Medical imaging in pharmaceutical clinical trials: what radiologists should know,” Clinical Radiology, vol. 60, no. 10, pp. 1051–1057, 2005. View at Publisher · View at Google Scholar · View at Scopus